Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginkgo leaf capsule is a botanical drug product derived from the leaves of *Ginkgo biloba*, containing standardized extracts of flavonoids and terpenoids. Developed by Shanghai Xinyi Baileda Pharmaceutical, it is currently in Phase III clinical trials in China for the treatment of primary open-angle glaucoma (POAG), specifically targeting patients with the traditional Chinese medicine (TCM) pattern of blood stasis and collateral obstruction. The drug's therapeutic effects are attributed to its ability to improve ocular blood flow, provide neuroprotection to retinal ganglion cells, and act as an antioxidant and platelet-activating factor (PAF) antagonist.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginkgo leaf capsule.